(2) Kinase Inhibitors: Dasatinib
It is important to note that regulatory investigations and legal proceedings are ongoing
Its clinical superiority, robust pipeline, and operational efficiency provide a formidable defense against competitive pressures
The secondary evaluation outcomes were alterations in blood urea nitrogen (BUN), uric acid (UA), estimated glomerular filtration rate (eGFR), urinary AKI biomarkers, renal fibrosis biomarkers (transforming growth factor- 1 (TGF- 1 ), connective tissue growth factor (CTGF)), and traditional Chinese medicine (TCM) symptoms
It also raises the risk of muscle loss and slows down your metabolism
Litigation is still in the beginning stages and no cases have been resolved yet